Peter M. Haverty

11.2k citations

38 papers · 3.4k · 1 hit paper · h-index 29

Impact in

Cancer Research top 2%
- Cancer Genomics and Diagnostics
Molecular Biology top 5%
- Epigenetics and DNA Methylation
- Hedgehog Signaling Pathway Studies
- Genomics and Chromatin Dynamics
- RNA modifications and cancer
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors

Papers in

Molecular Biology 31
- Gene expression and cancer classification 8
- Bioinformatics and Genomic Networks 7
- Genomics and Chromatin Dynamics 7
- Ubiquitin and proteasome pathways 4
- Molecular Biology Techniques and Applications 3
- Epigenetics and DNA Methylation 3
Cancer Research 10
- Cancer Genomics and Diagnostics 7

Co-authors: Zemin Zhang (7 shared papers)Richard Bourgon (7 shared papers)Lori S. Friedman (7 shared papers)John Chant (3 shared papers)Klaus P. Hoeflich (6 shared papers)Marcia Belvin (6 shared papers)Robert L. Yauch (4 shared papers)David Stokoe (3 shared papers)
Journals: Clinical Cancer Research (4 papers)Nucleic Acids Research (4 papers)Cancer Research (4 papers)PLoS ONE (3 papers)Genome biology (2 papers)
Partner nations: United States France Singapore

In The Last Decade

Peter M. Haverty

37 papers receiving 3.3k citations

Peter M. Haverty's Hit Papers

align trajectories log scale

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics 2014 · 269 citations

Peers

Countries citing papers authored by Peter M. Haverty

Since Specialization

Citations

This map shows the geographic impact of Peter M. Haverty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Haverty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Haverty more than expected).

Fields of papers citing papers by Peter M. Haverty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Haverty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Haverty. The network helps show where Peter M. Haverty may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter M. Haverty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter M. Haverty Line = papers co-authored together Peter M. Haverty links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma Cancer Cell ·Hayley J. Sharpe, Grégoire Pau, Gerrit J.P. Dijkgraaf, Nicole Basset‐Séguin, Zora Modrušan, Thomas Januario, Vickie Tsui, Alison B. Durham, Andrzej A. Dlugosz, Peter M. Haverty, Richard Bourgon, Jean Y. Tang, Kavita Y. Sarin, Luc Dirix, David C. Fisher, Charles M. Rudin, Howard Sofen, Michael R. Migden, Robert L. Yauch, Frédéric J. de Sauvage	2015	296
2	Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics Arthritis Research & Therapy ·Glynn Dennis, Cécile Holweg, Sarah Kummerfeld, David F. Choy, Audi Setiadi, Jason A. Hackney, Peter M. Haverty, Houston Gilbert, Wei Lin, Lauri Diehl, Sven Fischer, An Song, David Musselman, Micki Klearman, Cem Gabay, Arthur Kavanaugh, Judith Endres, David A. Fox, Flavius Martin, Michael J. Townsend Hit paper breakdown →	2014	269
3	Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation Cell Reports ·Ryan Raisner, Samir Kharbanda, Lingyan Jin, Edwin E. Jeng, Emily Chan, Mark Merchant, Peter M. Haverty, Russell Bainer, Tommy K. Cheung, David Arnott, E. Megan Flynn, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne	2018	232
4	Reproducible pharmacogenomic profiling of cancer cell line panels Nature ·Peter M. Haverty, Eva Lin, Jenille Tan, Yihong Yu, Billy Lam, Steve Lianoglou, Richard M. Neve, Scott E. Martin, Jeff Settleman, Robert L. Yauch, Richard Bourgon	2016	186
5	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Molecular Cancer Research ·Xiaolan Hu, Howard M. Stern, Lin Ge, Carol O’Brien, Lauren E. Haydu, Cynthia D. Honchell, Peter M. Haverty, Brock A. Peters, Thomas D. Wu, Lukas C. Amler, John Chant, David Stokoe, Mark R. Lackner, Guy Cavet	2009	177
6	Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells Proceedings of the National Academy of Sciences ·Christy C. Ong, Adrian M. Jubb, Peter M. Haverty, Wei Zhou, Victoria Tran, Tom Truong, Helen Turley, (unknown), Domagoj Vucic, Adrian L. Harris, Marcia Belvin, Lori S. Friedman, Elizabeth M. Blackwood, Hartmut Koeppen, Klaus P. Hoeflich	2011	170
7	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors Molecular Cancer Therapeutics ·Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John G. Moffat, Marcia Belvin, Mark R. Lackner	2012	158
8	Transposable element expression in tumors is associated with immune infiltration and increased antigenicity Nature Communications ·Yu Kong, Christopher M. Rose, Ashley Cass, Alexander Williams, Martine Darwish, Steve Lianoglou, Peter M. Haverty, Ann-Jay Tong, Craig Blanchette, Matthew L. Albert, Ira Mellman, Richard Bourgon, John M. Greally, Suchit Jhunjhunwala, Haiyin Chen‐Harris	2019	156
9	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner	2012	151
10	Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes Cancer Research ·Genee Y. Lee, Peter M. Haverty, Li Li, Noelyn M. Kljavin, Richard Bourgon, James Lee, Howard M. Stern, Zora Modrušan, Somasekar Seshagiri, Zemin Zhang, David Davis, David Stokoe, Jeffrey Settleman, Frédéric J. de Sauvage, Richard M. Neve	2014	125
11	High‐resolution genomic and expression analyses of copy number alterations in breast tumors Genes Chromosomes and Cancer ·Peter M. Haverty, Jane Fridlyand, Li Li, Gad Getz, Rameen Beroukhim, Scott Lohr, Thomas D. Wu, Guy Cavet, Zemin Zhang, John Chant	2008	117
12	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer Cancer Research ·Lingyan Jin, Jesse Garcia, Emily Chan, Cecile de la Cruz, Ehud Segal, Mark Merchant, Samir Kharbanda, Ryan Raisner, Peter M. Haverty, Zora Modrušan, Justin Q. Ly, Edna F. Choo, Susan Kaufman, Maureen H. Beresini, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne	2017	109
13	Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Cancer Research ·Joshua S. Kaminker, Yan Zhang, Allison Waugh, Peter M. Haverty, Brock A. Peters, Dragan Sebisanovic, Jeremy Stinson, William F. Forrest, J. Fernando Bazán, Somasekar Seshagiri, Zemin Zhang	2007	104
14	Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab Clinical Cancer Research ·Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, Tom Truong, Peter M. Haverty, Jeffrey Eastham‐Anderson, Nicholas Lewin‐Koh, Bert Gunter, Marcia Belvin, Lesley Murray, Lori S. Friedman, Mark X. Sliwkowski, Klaus P. Hoeflich	2009	104
15	Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis Molecular & Cellular Proteomics ·Steffan Vartanian, P. Taylur, James Lee, Peter M. Haverty, Donald S. Kirkpatrick, Kebing Yu, David Stokoe	2015	96
16	Computational inference of transcriptional regulatory networks from expression profiling and transcription factor binding site identification Nucleic Acids Research ·Peter M. Haverty	2004	90
17	Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis Cell Metabolism ·Nisebita Sahu, Darlene Dela Cruz, Min Gao, Wendy Sandoval, Peter M. Haverty, Jinfeng Liu, Jean-Philippe Stéphan, Benjamin Haley, Marie Classon, Georgia Hatzivassiliou, Jeff Settleman	2016	86
18	MBASED: allele-specific expression detection in cancer tissues and cell lines Genome biology ·Oleg Mayba, Houston Gilbert, Jinfeng Liu, Peter M. Haverty, Suchit Jhunjhunwala, Zhaoshi Jiang, Colin Watanabe, Zemin Zhang	2014	82
19	High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors BMC Medical Genomics ·Peter M. Haverty, Lawrence Hon, Joshua S. Kaminker, John Chant, Zemin Zhang	2009	80
20	Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration Proceedings of the National Academy of Sciences ·Yoong Wearn Lim, Haiyin Chen‐Harris, Oleg Mayba, Steve Lianoglou, Arthur Wüster, Tushar Bhangale, Zia Khan, Sanjeev Mariathasan, Anneleen Daemen, Jens Reeder, Peter M. Haverty, William F. Forrest, Matthew J. Brauer, Ira Mellman, Matthew L. Albert	2018	74

About Peter M. Haverty

Peter M. Haverty is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 38 papers that have together received 3.4k indexed citations. Recurring topics across this work include Gene expression and cancer classification (8 papers), Cancer Genomics and Diagnostics (7 papers), Bioinformatics and Genomic Networks (7 papers), Genomics and Chromatin Dynamics (7 papers), Ubiquitin and proteasome pathways (4 papers), Cancer-related Molecular Pathways (4 papers), Molecular Biology Techniques and Applications (3 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Cancer Research (572 citations), Molecular Biology (2.2k citations), Oncology (735 citations), Rheumatology (212 citations) and Pathology and Forensic Medicine (231 citations). Peter M. Haverty has collaborated with scholars based in United States, France and Singapore. Frequent co-authors include Zemin Zhang, Richard Bourgon, Lori S. Friedman, John Chant, Klaus P. Hoeflich, Marcia Belvin, Robert L. Yauch, David Stokoe, Karen E. Gascoigne and Steve Lianoglou. Their work appears in journals such as Clinical Cancer Research, Nucleic Acids Research, Cancer Research, PLoS ONE and Genome biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Peter M. Haverty

Impact in

Papers in i

In The Last Decade

Peter M. Haverty

Peter M. Haverty's Hit Papers

Peers

Countries citing papers authored by Peter M. Haverty

Fields of papers citing papers by Peter M. Haverty

All Works

About Peter M. Haverty

Explore authors with similar magnitude of impact

Papers in